ESTIMATING THE MICROVASCULAR BENEFITS OF SCREENING FOR TYPE 2 DIABETES MELLITUS
- 1 January 2000
- journal article
- research article
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 16 (03) , 822-833
Abstract
Objective: To define the relative benefits of screening for diabetes and improved treatment programs and ways of improving the efficiency of screening for a population-based cohort derived from the Third National Health and Nutrition Examination Survey (NHANES III).Methods: A Markov decision model is used to estimate microvascular benefits of glucose control for four different screening and treatment scenarios, including either universal screening or improved glucose control of known diabetic subjects, neither, or both.Results: A population cohort of subjects with recent onset of diabetes (<5 years) was derived from NHANES III (of whom close to half were unaware that they had diabetes). In this population-based cohort, the total benefit achievable by universal screening and improved treatment (limiting HbA1c to less than 9%) is a reduction of about 30,000 cases of blindness over the lifetime of the cohort. Screening alone results in 7% of this benefit, and improved treatment alone provides 65%. Screening a targeted group of patients with three or more risk factors for developing diabetes would reduce the number of required fasting glucose measurements needed by 82% and provide 50% of the total benefit of screening the entire population with a fasting glucose measurement.Conclusions: Morbidity from type 2 diabetes can be most effectively reduced by developing ways to modestly improve the glycemic control of known diabetic subjects, particularly those with high A1c's and early onset of disease. Targeting can significantly reduce the number of persons who need to be screened with a fasting blood test while preserving a large component of the benefit of screening.Keywords
This publication has 15 references indexed in Scilit:
- The cost-effectiveness of screening for type 2 diabetes1998
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Estimated Benefits of Glycemic Control in Microvascular Complications in Type 2 DiabetesAnnals of Internal Medicine, 1997
- United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications in Non-Insulin-dependent Diabetes MellitusAnnals of Internal Medicine, 1996
- Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM): Results of the feasibility trialDiabetes Care, 1995
- A New and Simple Questionnaire to Identify People at Increased Risk for Undiagnosed DiabetesDiabetes Care, 1995
- Ten-year Incidence of Visual Loss in a Diabetic PopulationOphthalmology, 1994
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993
- Relation of ocular and systemic factors to survival in diabetesArchives of internal medicine (1960), 1989
- Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatmentJAMA, 1978